Skip to main content

Coronavirus (COVID-19) Updates: Visitation Policies (New! 11.25.20) | How We're Keeping You Safe | Latest COVID Information

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

E4512 ALCHEMIST ALK+ A Phase III early stage NSCLC Crizotinib vs Observation

Research Question:
Does the drug crizotinib treat patients with non-small cell lung cancer?

Basic Study Information

Purpose:
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.

Location: Highland Hospital

Lead Researcher (Principal Investigator)

Lead Researcher:  Yuhchyau Chen

Study Contact Information

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search